News articles about Globus Medical (NYSE:GMED) have been trending somewhat positive recently, Accern Sentiment reports. The research firm rates the sentiment of news coverage by analyzing more than twenty million blog and news sources. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Globus Medical earned a daily sentiment score of 0.17 on Accern’s scale. Accern also gave media stories about the medical device company an impact score of 45.963358786375 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the next several days.

Here are some of the media stories that may have impacted Accern Sentiment’s rankings:

Shares of Globus Medical (NYSE:GMED) opened at $43.28 on Thursday. Globus Medical has a 12-month low of $25.67 and a 12-month high of $46.51. The company has a market capitalization of $4,140.00, a PE ratio of 39.35, a PEG ratio of 2.65 and a beta of 0.56.

Globus Medical (NYSE:GMED) last posted its earnings results on Wednesday, November 8th. The medical device company reported $0.30 EPS for the quarter, meeting the Zacks’ consensus estimate of $0.30. Globus Medical had a return on equity of 13.67% and a net margin of 17.54%. The firm had revenue of $151.74 million for the quarter, compared to analysts’ expectations of $150.73 million. During the same period last year, the firm earned $0.29 EPS. The company’s quarterly revenue was up 11.9% on a year-over-year basis. research analysts forecast that Globus Medical will post 1.27 EPS for the current year.

GMED has been the topic of several analyst reports. Barclays cut their price target on Globus Medical from $28.00 to $27.00 and set an “underweight” rating on the stock in a research report on Thursday, October 19th. ValuEngine downgraded Globus Medical from a “buy” rating to a “hold” rating in a research report on Friday, December 1st. BidaskClub raised Globus Medical from a “hold” rating to a “buy” rating in a research report on Tuesday, November 14th. Zacks Investment Research downgraded Globus Medical from a “hold” rating to a “sell” rating in a research report on Thursday, January 4th. Finally, Piper Jaffray Companies restated a “buy” rating on shares of Globus Medical in a research report on Thursday, October 19th. One equities research analyst has rated the stock with a sell rating, five have given a hold rating and nine have assigned a buy rating to the company. The company currently has an average rating of “Buy” and a consensus price target of $40.57.

In related news, CAO Steven Payne sold 3,076 shares of the firm’s stock in a transaction dated Friday, December 15th. The shares were sold at an average price of $39.30, for a total value of $120,886.80. Following the transaction, the chief accounting officer now directly owns 23,847 shares of the company’s stock, valued at approximately $937,187.10. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, President Anthony L. Williams sold 15,000 shares of the firm’s stock in a transaction dated Wednesday, December 13th. The shares were sold at an average price of $38.30, for a total transaction of $574,500.00. Following the completion of the transaction, the president now directly owns 15,000 shares in the company, valued at $574,500. The disclosure for this sale can be found here. Insiders have sold a total of 124,908 shares of company stock worth $4,747,975 over the last 90 days. Insiders own 28.21% of the company’s stock.

WARNING: “Globus Medical (GMED) Given Media Sentiment Score of 0.17” was first published by TheOlympiaReport and is the property of of TheOlympiaReport. If you are viewing this news story on another site, it was stolen and reposted in violation of international trademark & copyright law. The original version of this news story can be read at https://theolympiareport.com/2018/01/18/globus-medical-gmed-given-media-sentiment-score-of-0-17.html.

About Globus Medical

Globus Medical, Inc (Globus) is a medical device company focused on the design, development and commercialization of musculoskeletal implants that promote healing in patients with spine disorders. The Company is focused on implants that promote healing in patients with spine disorders. The Company’s products fall into one of two categories: Innovative Fusion or Disruptive Technologies.

Insider Buying and Selling by Quarter for Globus Medical (NYSE:GMED)

Receive News & Ratings for Globus Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Globus Medical and related companies with MarketBeat.com's FREE daily email newsletter.